Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

124.94 -0.67 (-0.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Via ACCESSWIRE
Moderna to Present at Upcoming Conferences in June 2023
Via ACCESSWIRE
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in Tuesday Morning Trading
Via Investor Brand Network
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Via ACCESSWIRE
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
Via ACCESSWIRE
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
Via ACCESSWIRE
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Via ACCESSWIRE
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
Exposures COVID-19
3 Underperforming Nasdaq 100 Stocks Worth a Closer Look
Given the volatility and growth potential associated with the Nasdaq’s elite, investors may want to keep these recent underperformers on the watch list. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
Via ACCESSWIRE
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
Via ACCESSWIRE
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures Economy Intellectual Property Product Safety
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
Via ACCESSWIRE
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV
Via ACCESSWIRE
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
Via ACCESSWIRE
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Via ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Via ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
From Generation Bio Co.; Moderna
Via GlobeNewswire
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
Via ACCESSWIRE
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Moderna to Present at Cowen's 43rd Annual Health Care Conference
Via ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
Via ACCESSWIRE
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.